EUCTR2017-000576-29-EE进行中（未招募）1 期
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306) - CARMEN CD 306
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,032
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study.
- •1. Subjects and/or their parent or legally authorized representative must have an understanding, ability, and willingness to fully comply with study procedures and restrictions.
- •2. Subjects must be able to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent and assent as applicable to participate in the study.
- •3. Subjects must be between =16 and =80 years of age at the time of the signing of the informed consent/assent form. Note: Subjects <18 years of age must weigh =40 kg and must have body mass index =16.5 kg/m2.
- •4. Subjects must have active moderate to severe ileal (terminal ileum), ileocolic, or colonic CD at baseline (Visit 2) as defined by:
- •a. CDAI score between 220 and 450 (inclusive) AND
- •b. Presence of ulcerations that are characteristic to CD, as determined by a colonoscopy performed during screening, and as defined by the SES-CD >6 (SES-CD =4 for isolated ileitis) AND
- •c. Meeting the following subscores in the 2-item PRO:
- •i. Abdominal pain subscore =5 (average worst daily pain on the 11-point numerical rating scale [NRS]) AND abdominal pain subscore >2 (average daily pain on the 4-point abdominal pain variable of CDAI)over the 7 most recent days out of the 10 days before colonoscopy preparation (may or may not be contiguous) AND/OR
- •ii. Average of the daily stool frequency subscore =4 of type 6/7 (very soft stools/liquid stools) as shown in the Bristol Stool Form Scale (BSFS) over the 7 most recent days out of the 10 days before colonoscopy preparation (may or may not be contiguous).
- •5. Subjects must have a documented diagnosis (endoscopic with histology) of CD for =3 months before screening. Documented diagnosis is defined as:
- •? - A biopsy report to confirm the histological diagnosis AND
- •? - A report documenting disease duration based upon prior colonoscopy.
- •Note: If a biopsy report is not available in the source document at the time of screening, a biopsy must be performed during the screening colonoscopy and the histology report should be consistent with the CD diagnosis. If the histology diagnosis is not clear at this time point, the subject should not be randomized.
- •6. Subjects must be willing and able to undergo a colonoscopy during screening after all other inclusion criteria have been met.
- •7. Subjects must have had an inadequate response to, or lost response to, or had an intolerance to at least 1 conventional treatment such as sulfasalazine or mesalamine (5-aminosalicylic acid [5-ASA]), glucocorticoids, immunosuppressants (azathioprine [AZA], 6-mercaptopurine [6-MP], or
- •methotrexate [MTX]), or anti-TNF (refer to Appendix 4 for guidance). Subjects who have had an inadequate response to sulfasalazine or mesalamine should have also failed at least 1 other conventional treatment such as glucocorticoids.
- •8. Subjects receiving any treatment(s) for CD described in Section 5.2.1 of the protocol are eligible provided they have been, and are anticipated to be, on a stable dose for the designated period of time.
- •9. Subjects are males or nonpregnant, nonlactating females who, if sexually active, agree to comply with the contraceptive requirements of the protocol, or females of nonchildbearing potential. Males and females of reproductive potential who are sexually active must agree to use appropriate contraception for the duration of the s
排除标准
- •Subjects are excluded from the study if any of the following exclusion criteria are met.
- •1. Subjects with indeterminate colitis, microscopic colitis, non-steroidal anti-inflammatory drug-induced colitis, ischemic colitis, infectious colitis, or clinical/histologic findings suggestive of ulcerative colitis.
- •2. Subjects with colonic dysplasia or neoplasia. (Subjects with prior history of adenomatous polyps will be eligible if the polyps have been completely removed.)
- •3. Subjects with past medical history or presence of toxic megacolon.
- •4. Subjects with presence of enterovesical (ie, between the bowel and urinary bladder) or enterovaginal fistulae.
- •5. Subjects with current symptomatic diverticulitis or diverticulosis.
- •6. Subjects with obstructive colonic stricture, past medical history of colonic resection, a history of bowel surgery within 6 months before screening, or who are likely to require surgery for CD during the treatment period.
- •7. Subjects with past medical history of multiple small bowel resections resulting in clinically significant short bowel syndrome.
- •8. Subjects requiring total parenteral nutrition.
- •9. Subjects with past medical history of bowel surgery resulting in an existing or current stoma. Subjects who had a j-pouch are excluded as a j-pouch could result in a stoma.
- •10. Subjects have had prior treatment with SHP647 (formerly PF-00547659).
- •11. Subjects with known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds, or any of the stated ingredients.
- •12. Subjects have received any nonbiologic treatment with immunomodulatory properties (other than AZA, 6-MP, or MTX) or continuous antibiotics (>2 weeks) for the treatment of CD within 30 days before baseline (Visit 2).
- •13. Subjects have received anti-TNF treatment within 60 days before baseline (Visit 2).
- •14. Subjects have received any biologic with immunomodulatory properties (other than anti-TNFs) within 90 days before baseline (Visit 2).
- •15. Subjects have ever received anti-integrin/adhesion molecule treatment (eg, natalizumab, vedolizumab, efalizumab, etrolizumab, or any other investigational anti-integrin/adhesion molecule).
- •16. Subjects have received lymphocytes apheresis or selective monocyte granulocytes apheresis within 60 days before baseline (Visit 2).
- •17. Subjects have received enteral nutrition treatment within 30 days before baseline (Visit 2).
- •18. Subjects have received parenteral or rectal glucocorticoids or rectal 5-ASA within 14 days before screening colonoscopy.
- •19. Subjects have taken >20 mg/day of prednisone or equivalent oral systemic corticosteroid dose within 14 days before baseline (Visit 2) or have taken =40 mg/day of prednisone or equivalent oral systemic corticosteroid dose within 6 weeks before baseline (Visit 2).
- •20. Subjects have participated in other investigational studies within either 30 days or 5 half-lives of investigational product used in the study (whichever is longer) before screening (Visit 1).
- •21. Subjects have received a live (attenuated) vaccine within 30 days before the baseline visit (Visit 2).
- •22. Subjects with active enteric infections (positive stool culture and sensitivity), Clostridium difficile infection or pseudomembranous colitis [subjects with C. difficile infection at screening may be allowed retest after treatment], evidence of active cytomegalovirus infection or Listeria monocytogenes, known active invasive fungal infections such as histop
研究者
相似试验
进行中（未招募）
1 期
DIAMOND - A study to see if pimodivir in combination with standard of care treatment is useful and safe in the treatment of adolescent, adult and elderly non-hospitalized subjects with influenza A infection who are at risk of developing complications.EUCTR2017-002217-59-LTJanssen-Cilag International NV720
进行中（未招募）
1 期
Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.MedDRA version: 20.0Level: LLTClassification code 10011402Term: Crohn's disease (colon)System Organ Class: 100000004856Crohn's diseaseEUCTR2017-000617-23-GRShire Human Genetic Therapies, Inc.983
进行中（未招募）
1 期
DIAMOND - A study to see if pimodivir in combination with standard of care treatment is useful and safe in the treatment of adolescent, adult and elderly non-hospitalized subjects with influenza A infection who are at risk of developing complications.Influenza A InfectionMedDRA version: 20.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862EUCTR2017-002217-59-GBJanssen-Cilag International NV720
进行中（未招募）
1 期
SAPPHIRE - A study to see if pimodivir in combination with standard of care treatment is useful and safe in the treatment of adolescent, adult and elderly hospitalized patients with influenza A infection.EUCTR2017-002156-84-ATJanssen-Cilag International NV600
进行中（未招募）
1 期
Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Ulcerative Colitis, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)(FIGARO UC 302).lcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-000572-28-SKShire Human Genetic Therapies, Inc.825